EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Small Bowel Neuroendocrine Neoplasms: A Single Tertiary Center Real World Experience

Rucsandra-Ilinca Diculescu, Doina Istratescu, Tudor Stroie, Ana-Gabriela Prada, Adina Emilia Croitoru, Vlad M Croitoru, Vladislav Brașoveanu, Traian Dumitrașcu, Gabriel Becheanu, Vlad Herlea, Ioana Gabriela Lupescu, Mugur Cristian Grasu und 5 weitere

Journal of Gastrointestinal and Liver Diseases · 2025

DOI: 10.15403/jgld-6433 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, 2025. Verfasst von Rucsandra-Ilinca Diculescu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest; 2 Department of Gastroenterology and Hepatology, Fundeni Clinical I…. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Intestinal Neoplasms, Intestine, Small. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Small bowel neuroendocrine neoplasms (SB-NENs) are a rare type of tumor that is clinically challenging and is often diagnosed in advanced stages. This retrospective study aimed to characterize the clinical presentation, diagnostic workup, and therapeutic strategies, as well as to evaluate the prognosis of patients managed in a tertiary care center in Bucharest, Romania, over five years.

Methods

We conducted an observational, retrospective cohort study on 42 cases of SB-NEN evaluated at our center between January 1, 2020, and March 31, 2025. Data regarding clinicopathological characteristics, treatments, and disease evolution were summarized. Overall survival was estimated at 1, 3, and 5 years.

Results

Computed tomography was the most frequently used imaging method for diagnosis (52.4%). Surgery was the most adopted method for obtaining the pathological specimen, used in 70.7% of cases. The majority of tumors were well-differentiated (85.6%). The overall survival distribution showed a median survival time of 94 months. The cumulative proportion of patients surviving at 1 year was 97.6%, at 3 years was 89.3% and at 5 years was 75.7%. There was a significant difference in overall survival stratified by tumor grading (p=0.006), indicating that this was a significant prognostic factor; the metastatic status and large tumors showed a trend toward statistical significance, but they did not meet the conventional threshold (p=0.068 and 0.103, respectively).

Conclusions

SB-NEN showed favorable outcomes, with surgery improving survival even in some metastatic cases. Lower tumor grade was associated with a better prognosis, while somatostatin analogues (SSA) therapy showed no survival benefit. Patients with large tumors and metastatic disease also showed a trend towards reduced survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsIntestinal NeoplasmsIntestine, SmallHumansMaleFemaleRetrospective StudiesMiddle AgedRomaniaAgedTertiary Care CentersAdultPrognosisTomography, X-Ray ComputedNeoplasm GradingAged, 80 and over

Autor:innen und Institutionen

  • Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest; 2 Department of Gastroenterology and Hepatology, Fundeni Clinical Institute, Bucharest, Romania. ridiculescu@yahoo.com.
  • Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest; 2 Department of Gastroenterology and Hepatology, Fundeni Clinical Institute, Bucharest, Romania. doina.proca08@gmail.com.
  • Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest; 2 Department of Gastroenterology and Hepatology, Fundeni Clinical Institute, Bucharest, Romania. tudor-gheorghe.stroie@umfcd.ro.
  • Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest; Clinical Department of Geriatrics and Gerontology, "Saint Luke", Hospital of Chronic Diseases, Bucharest, Romania. ana-gabriela.prada@drd…
  • Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest; Department of Oncology, Fundeni Clinical Institute, Bucharest, Romania. adina.croitoru09@yahoo.com.
  • Department of Oncology, Fundeni Clinical Institute, Bucharest, Romania. vlad.m.croitoru@gmail.com.

Zitieren

APA

Diculescu, R. I., Istratescu, D., Stroie, T., Prada, A. G., Croitoru, A. E., Croitoru, V. M., Brașoveanu, V., Dumitrașcu, T., Becheanu, G., Herlea, V., Lupescu, I. G., Grasu, M. C., Constantinescu, G., Mănuc, M., Gheorghe, C., Gheorghe, L., & Poiană, C. (2025). Small Bowel Neuroendocrine Neoplasms: A Single Tertiary Center Real World Experience. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-6433

Vancouver

Diculescu RI, Istratescu D, Stroie T, Prada AG, Croitoru AE, Croitoru VM, et al. Small Bowel Neuroendocrine Neoplasms: A Single Tertiary Center Real World Experience. Journal of Gastrointestinal and Liver Diseases. 2025. doi:10.15403/jgld-6433

BibTeX
@article{Diculescu2025,
  author = {Diculescu, Rucsandra-Ilinca and Istratescu, Doina and Stroie, Tudor and Prada, Ana-Gabriela and Croitoru, Adina Emilia and Croitoru, Vlad M and Brașoveanu, Vladislav and Dumitrașcu, Traian and Becheanu, Gabriel and Herlea, Vlad and Lupescu, Ioana Gabriela and Grasu, Mugur Cristian and Constantinescu, Gabriel and Mănuc, Mircea and Gheorghe, Cristian and Gheorghe, Liana and Poiană, Cătălina},
  title = {Small Bowel Neuroendocrine Neoplasms: A Single Tertiary Center Real World Experience},
  journal = {Journal of Gastrointestinal and Liver Diseases},
  year = {2025},
  doi = {10.15403/jgld-6433}
}
Kostenlos starten →